Nilotinib

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bone Marrow Transplant Failure

Conditions

Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

Trial Timeline

Aug 1, 2010 → Dec 1, 2013

NCT ID

NCT01155817

About Nilotinib

Nilotinib is a phase 1 stage product being developed by Novartis for Bone Marrow Transplant Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT01155817. Target conditions include Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral.

What happened to similar drugs?

16 of 20 similar drugs in Bone Marrow Transplant Failure were approved

Approved (16) Terminated (1) Active (4)

✅Reclast (ZOL446, zoledronic acid)NovartisApproved

✅zoledronic acidNovartisApproved

✅Zoledronic acidNovartisApproved

✅Disodium pamidronate + PlaceboNovartisApproved

✅Zoledronic acidNovartisApproved

✅PamidronateNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04559555	Pre-clinical	Completed	—	—	Acute Lymphoblastic Leukemia (ALL)
NCT04498871	Pre-clinical	Completed	—	—	Hypereosinophilic Syndrome (HES)
NCT04518644	Pre-clinical	Completed	—	—	Chronic Myelogenous Leukemia (CML)
NCT02774512	Phase 1	Withdrawn	May 1, 2016	Nov 1, 2017	Colon Cancer
NCT02546674	Approved	Completed	Feb 18, 2016	Mar 25, 2021	Chronic Myeloid Leukemia
NCT02115386	Phase 3	Terminated	Dec 17, 2015	Oct 31, 2016	Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
NCT02353728	Phase 2	Completed	Jan 1, 2015	Feb 1, 2021	Chronic Myeloid Leukemia
NCT02108951	Phase 3	Terminated	Jul 7, 2014	Aug 10, 2016	Philidelphia Positive Chronic Myeloid Leukaemia
NCT01844765	Phase 2	Completed	Aug 20, 2013	Aug 28, 2020	Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
NCT01744665	Phase 2	Completed	Aug 12, 2013	Sep 29, 2018	CML
NCT01863745	Phase 2	Completed	Jun 25, 2013	Oct 2, 2023	Gastrointestinal Stromal Tumors
NCT03332511	Approved	Completed	May 6, 2013	Oct 24, 2016	Chronic Myeloid Leukemia, Chronic Phase
NCT01743989	Phase 3	Completed	Apr 15, 2013	Jul 8, 2020	Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
NCT01735955	Approved	Completed	Mar 29, 2013	Jul 7, 2023	Chronic Myelogenous Leukemia (CML)
NCT01698905	Phase 2	Completed	Dec 20, 2012	Jan 29, 2025	Chronic Myeloid Leukemia
NCT01562847	Pre-clinical	UNKNOWN	Jul 1, 2011	Jun 1, 2015	Chronic Myeloid Leukemia
NCT01077544	Phase 1	Completed	Apr 14, 2011	Jul 1, 2015	Chronic Myeloid Leukemia
NCT01254188	Phase 3	Completed	Apr 1, 2011	Nov 1, 2014	Chronic Myeloid Leukemia
NCT01274351	Phase 2	Completed	Jan 25, 2011	Aug 1, 2019	Chronic Myelogenous Leukemia
NCT01270893	Phase 2	Withdrawn	Jan 1, 2011	—	Gastrointestinal Cancer

Competing Products

20 competing products in Bone Marrow Transplant Failure

See all competitors

Product	Company	Stage	Hype Score
Denosumab + Zoledronic Acid	Daiichi Sankyo	Phase 3	40
Enzalutamide	Astellas Pharma	Phase 2	35
Enzalutamide	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Merestinib	Eli Lilly	Phase 1	21
FORTEO + Placebo	Eli Lilly	Phase 1	29
Arzoxifene + Placebo	Eli Lilly	Phase 3	40
Tanezumab	Eli Lilly	Phase 3	40
Anastrozole + Tamoxifen	AstraZeneca	Phase 3	40
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Zoledronic acid + Letrozole	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Reclast (ZOL446, zoledronic acid)	Novartis	Approved	43
Zoledronic acid	Novartis	Phase 3	32
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid	Novartis	Phase 3	40
zoledronic acid	Novartis	Phase 1	29
Ruxolitinib continuous therapy	Novartis	Phase 2	39
zoledronic acid	Novartis	Approved	43